分化型甲状腺癌初始治疗反应极佳患者的随访策略:少即是多
这项历史性队列研究纳入1359例甲状腺全切除加放射性碘残余消融后反应极佳的分化型甲状腺癌患者,中位随访8.7年间仅13例(1%)出现结构性复发,均为局部区域复发且发现较晚(中位5.5年),复发时62%患者非刺激状态下血清甲状腺球蛋白稳定低于0.2 ng/mL;作者结论认为对反应极佳患者应降低颈部超声及血清甲状腺球蛋白和抗甲状腺球蛋白抗体监测的强度和频率,尤其在初始治疗后五年内。
要点
- 1359例反应极佳患者中位随访8.7年仅13例(1%)出现结构性复发,均为局部区域复发。
- 复发发现较晚,中位为初始手术后5.5年,范围3.6至10.7年。
- 复发时62%患者非刺激血清甲状腺球蛋白稳定低于0.2 ng/mL。
核心结论
- 反应极佳的分化型甲状腺癌患者结构性复发发现相对较晚,作者认为应降低颈部超声及血清甲状腺球蛋白和抗甲状腺球蛋白抗体监测的强度和频率,尤其在初始治疗后五年内。
研究设计与样本
- 历史性队列研究,纳入1359例甲状腺全切除加放射性碘残余消融后反应极佳的分化型甲状腺癌患者。
主要发现
- 1359例患者中703例(54%)按第七版肿瘤淋巴结转移分期系统为I期,987例(73%)按美国甲状腺协会初始治疗后风险分层为中间风险。
- 中位随访8.7年间仅13例(1%)确诊结构性复发,均为局部区域复发,无远处转移。
- 复发中位发现时间为初始手术后5.5年,范围3.6至10.7年,全部经颈部超声检出。
- 复发时4例(31%)非刺激血清甲状腺球蛋白可检出(≥0.2 ng/mL),1例(8%)血清抗甲状腺球蛋白抗体阳性,8例(62%)非刺激血清甲状腺球蛋白稳定低于0.2 ng/mL。
- 除上述13例外,随访结束时另有14例存在生化持续性疾病。
临床怎么用
- 作者认为对初始治疗反应极佳的分化型甲状腺癌患者,应降低颈部超声及血清甲状腺球蛋白和抗甲状腺球蛋白抗体监测的强度和频率,尤其在初始治疗后五年内。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of recurrence in patients with differentiated thyroid cancer (DTC) can be estimated based on their response to initial therapy. The aim of this study was to evaluate an adequate follow-up strategy for DTC patients with an excellent response by assessing the characteristics of structural recurrence. METHODS: This historical cohort study included 1359 DTC patients who had excellent response to total thyroidectomy with radioactive iodine remnant ablation. RESULTS: Among 1359 patients, 703 (54%) patients were classified as stage I according to the seventh tumor node metastasis staging system, and 987 (73%) patients were classified as intermediate risk according to the American Thyroid Association's risk stratification after initial therapy. During a median of 8.7 years of follow-up, only 13 (1%) patients were confirmed to have structural recurrence. All of the recurrences were locoregional disease, and there were no distant metastases. Recurrences were detected late at a median of 5.5 years after the initial surgery (range 3.6-10.7 years). All structural recurrences were detected on neck ultrasonography. Non-stimulated serum thyroglobulin (Tg) was detectable (≥0.2 ng/mL) in four (31%) patients, and serum anti-Tg antibodies were positive in one (8%) patient. However, non-stimulated serum Tg levels were stably low (<0.2 ng/mL) in eight (62%) patients when recurrences were detected. In addition to these 13 patients, 14 patients also presented with biochemical persistent disease at the end of follow-up. CONCLUSIONS: Recurrences of DTC in patients with an excellent response to initial therapy were detected relatively late. The intensity and frequency of follow-up of neck ultrasonography as well as serum Tg and anti-Tg antibody measurements should be reduced, especially within five years of the initial therapy, in DTC patients who have an excellent response.
引用
- Jeon MJ, Kim M, Park S, et al. A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better. Thyroid. 2018. PMID: 29179642. doi:10.1089/thy.2017.0130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。